FibroGen, Inc. (BMV:FGEN)

Market Cap	791.21M
Revenue (ttm)	138.53M
Net Income (ttm)	-38.96M
Shares Out	n/a
EPS (ttm)	-9.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8
Average Volume	41
Open	205.00
Previous Close	210.00
Day's Range	205.00 - 205.00
52-Week Range	105.00 - 385.00
Beta	0.77
RSI	59.54
Earnings Date	Nov 3, 2025

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 225
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: FGEN

Financial Performance

In 2024, FibroGen's revenue was $29.62 million, a decrease of -36.71% compared to the previous year's $46.80 million. Losses were -$47.58 million, -83.26% less than in 2023.

Financial numbers in USD